These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 27404028)

  • 21. Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.
    Morga A; Ajmera M; Gao E; Patterson-Lomba O; Zhao A; Mancuso S; Siddiqui E; Kagan R
    Menopause; 2024 Jan; 31(1):68-76. PubMed ID: 38016166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of conjugated estrogens/bazedoxifene on lipid and coagulation variables: a randomized placebo- and active-controlled trial.
    Skouby SO; Pan K; Thompson JR; Komm BS; Mirkin S
    Menopause; 2015 Jun; 22(6):640-9. PubMed ID: 25405570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tissue-selective estrogen complexes for postmenopausal women.
    Mirkin S; Komm BS
    Maturitas; 2013 Nov; 76(3):213-20. PubMed ID: 23849704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1).
    Simon JA; Anderson RA; Ballantyne E; Bolognese J; Caetano C; Joffe H; Kerr M; Panay N; Seitz C; Seymore S; Trower M; Zuurman L; Pawsey S
    Menopause; 2023 Mar; 30(3):239-246. PubMed ID: 36720081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Most bothersome symptom in women with genitourinary syndrome of menopause as a moderator of treatment effects.
    Pinkerton JV; Bushmakin AG; Abraham L; Cappelleri JC; Komm BS
    Menopause; 2016 Oct; 23(10):1092-101. PubMed ID: 27404026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hot flush symptom-free days with bazedoxifene/conjugated estrogens in postmenopausal women.
    Yu H; Racketa J; Chines AA; Mirkin S
    Climacteric; 2013 Apr; 16(2):252-7. PubMed ID: 23035721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
    Bachmann G; Bobula J; Mirkin S
    Climacteric; 2010 Apr; 13(2):132-40. PubMed ID: 19863455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause.
    Pinkerton JV; Simon J; Panay N; Seitz C; Parke S; Caetano C; Mellinger U; Haseli Mashhadi N; Haberland C; Atanackovic G; Holz C; Mao G; Morrison M; Nisius S; Schaefers M; Zuurman L
    Menopause; 2024 Jun; 31(6):522-529. PubMed ID: 38564691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative controlled trial of a novel oral estrogen therapy, estradiol acetate, for relief of menopause symptoms.
    Utian WH; Speroff L; Ellman H; Dart C
    Menopause; 2005; 12(6):708-15. PubMed ID: 16278614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of Chinese herbal medicines (CHM) on menopausal symptoms compared to hormone replacement therapy (HRT) and placebo.
    Kwee SH; Tan HH; Marsman A; Wauters C
    Maturitas; 2007 Sep; 58(1):83-90. PubMed ID: 17689896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tissue-selective estrogen complex bazedoxifene and conjugated estrogens for the treatment of menopausal vasomotor symptoms.
    Stovall DW; Tanner-Kurtz K; Pinkerton JV
    Drugs; 2011 Sep; 71(13):1649-57. PubMed ID: 21902289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthetic conjugated estrogens-B and postmenopausal nocturnal vasomotor symptoms: a randomized controlled trial.
    Liu JH; Reape KZ; Hait HI
    Obstet Gynecol; 2012 Jan; 119(1):78-84. PubMed ID: 22183214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial.
    Cohen LS; Joffe H; Guthrie KA; Ensrud KE; Freeman M; Carpenter JS; Learman LA; Newton KM; Reed SD; Manson JE; Sternfeld B; Caan B; Freeman EW; LaCroix AZ; Tinker LF; Booth-Laforce C; Larson JC; Anderson GL
    Menopause; 2014 Apr; 21(4):347-54. PubMed ID: 23982113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initial investigation into the optimal dose ratio of conjugated estrogens and bazedoxifene: a double-blind, randomized, placebo-controlled phase 2 dose-finding study.
    Pickar JH; Lavenberg J; Pan K; Komm BS
    Menopause; 2018 Mar; 25(3):273-285. PubMed ID: 29088019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.
    Constantine GD; Revicki DA; Kagan R; Simon JA; Graham S; Bernick B; Mirkin S
    Menopause; 2019 May; 26(5):513-519. PubMed ID: 30516713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of women's treatment preferences for vasomotor symptoms due to menopause.
    Shiozawa A; Thurston RC; Cook E; Yang H; King DD; Kristy RM; Mancuso S
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(10):1117-1128. PubMed ID: 37650213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of fezolinetant on sleep disturbance and impairment during treatment of vasomotor symptoms due to menopause.
    Shapiro C M M; Cano A; Nappi RE; Santoro N; English ML; Mancuso S; Morga A; Siddiqui E; Valluri U; Ottery FD
    Maturitas; 2024 Aug; 186():107999. PubMed ID: 38749864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time to transient and stable reductions in hot flush frequency in postmenopausal women using conjugated estrogens/bazedoxifene.
    Pinkerton JV; Bushmakin AG; Abraham L; Komm BS; Bobula J
    Menopause; 2017 Sep; 24(9):1011-1016. PubMed ID: 28463874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA).
    Santoro N; Waldbaum A; Lederman S; Kroll R; Fraser GL; Lademacher C; Skillern L; Young J; Ramael S
    Menopause; 2020 Dec; 27(12):1350-1356. PubMed ID: 32769757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial.
    Pinkerton JV; Archer DF; Guico-Pabia CJ; Hwang E; Cheng RF
    Menopause; 2013 Jan; 20(1):38-46. PubMed ID: 23266839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.